Drug intelligence / Profile preview

PanCyte

Development stage: Preclinical
Lead developer: Constant Therapeutics
Modality: Peptides
Administration: Oral

Overview

PanCyte is a lanthionine-stabilized Angiotensin-(1-7) agonistic peptide. It was developed by Lanthio Pharma in partnership with US-based Tarix Pharmaceuticals for the treatment of pulmonary indications. Clinical development for PanCyte was anticipated to begin in 2013.

Targets

MAS1 (Mas receptor)

Beyond the preview

Go deeper on PanCyte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanCyte.

Explore the full profile